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Abstract Recent developments in medical biotechnology have facilitated to enhance the
production of monoclonal antibodies (mAbs) and recombinant proteins in mammalian cells.
Human mAbs for clinical applications have focused on three areas, particularly cancer,
immunological disorders, and infectious diseases. Tumor necrosis factor alpha (TNF-α), which
has both proinflammatory and immunoregulatory functions, is an important target in biophar-
maceutical industry. In this study, a humanized anti-TNF-α mAb producing stable CHO cell
line which produces a biosimilar of Humira (adalimumab) was used. Adalimumab is a fully
human anti-TNF mAb among the top-selling mAb products in recent years as a biosimilar.
Products from mammalian cell bioprocesses are a derivative of cell viability and metabolism,
which is mainly disrupted by cell death in bioreactors. Thus, different strategies are used to
increase the product yield. Suppression of apoptosis, also called anti-apoptotic cell engineer-
ing, is the most remarkable strategy to enhance lifetime of cells for a longer production period.
In fact, using anti-apoptotic cell engineering as a BioDesign approach was inspired by nature;
nature gives prolonged life span to some cells like stem cells, tumor cells, and memory B and
T cells, and researchers have been using this strategy for different purposes. In this study, as a
biomimicry approach, anti-apoptotic cell engineering was used to increase the anti-TNF-α
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A BioDesign Approach to Obtain High Yields
of Biosimilars by Anti-apoptotic Cell Engineering:
a Case Study to Increase the Production Yield of Anti-TNF
Alpha Producing Recombinant CHO Cells
mAb production from the humanized anti-TNF-αmAb producing stable CHO cell line by Bcl-
xL anti-apoptotic protein. It was shown that transient transfection of CHO cells by the Bcl-xL
anti-apoptotic protein expressing plasmid prolonged the cell survival rate and protected cells
from apoptosis. The transient expression of Bcl-xL using CHO cells enhanced the anti-TNF-α
production. The production of anti-TNF-α in CHO cells was increased up to 215 mg/L with an
increase of 160% after cells were transfected with Bcl-xL expressing plasmid with
polyethylenimine (PEI) reagent at the ratio of 1:6 (DNA:PEI). In conclusion, the anti-
apoptotic efficacy of the Bcl-xL expressing plasmid in humanized anti-TNF-α MAb produc-
ing stable CHO cells is compatible with curative effect for high efficiency recombinant protein
production. Thus, this model can be used for large-scale production of biosimilars through
transient Bcl-xL gene expression as a cost-effective method.
Keywords Anti-apoptotic cell engineering . Bcl-xL . Chinese hamster ovary cells .
Polyethylenimine (PEI) . Transient gene expression (TGE)
Introduction
Monoclonal antibodies (mAbs) have recently gained considerable importance both for diag-
nostic and therapeutic applications in biopharmaceutical industry [1–4]. When therapeutic
mAbs have succeeded in the treatment of immune diseases after entering clinical trials, the
production of mAbs has become the fastest moving industry [5]. The progress in researches of
mAb production is crucial from the point of lowering their production costs [6]. Tumor
necrosis factor alpha (TNF-α), which has both proinflammatory and immunoregulatory
functions, is an important target in biopharmaceutical industry [7–9]. Commercial TNF
antagonists comprise of engineered monoclonal antibodies and fusion proteins that have been
successfully used for the treatment of the chronic inflammatory diseases such as RA, Crohn’s
disease, and psoriasis [10, 11]. There are currently five TNF-α antibodies approved by the US
Food and Drug Administration (FDA) for clinical applications on the market either chimeric,
humanized, or fully human (i.e., etanercept, infliximab, adalimumab, certolizumab, and
golimumab) [12, 13]. Willrich et al. reported that FDA-approved TNF antagonists represent
approximately $20 billion in sales, and Humira (adalimumab), that is a top-selling drug of any
class in 2012, achieved solely an annual sale of 9.3 billion US dollars [14, 15]. Anti-TNF-α
agents are involved in important and promising group of drugs by virtue of prospects of
implementation in several immune-mediated inflammatory diseases, and their market share
and also biosimilars of anti-TNF-α agents are gaining importance. Thus, there is still a need to
develop new strategies that provide cheaper production of mAbs with higher efficacy in the
biopharmaceutical industry.
Mammalian cell lines are mostly the preferred expression systems for producing
biopharmaceuticals due to their capability for production of complex proteins with post-
translational modifications (such as glycosylation) as is the case with proteins produced in
humans [16, 17]. Chinese hamster ovary (CHO) cells, human embryonic kidney 293 (HEK
293) cells, murine myeloma cells (NS0 and Sp2/0), and baby hamster kidney (BHK21) cells
are the most prevalent non-human, mammalian cell lines used for recombinant protein
production [18]. Recombinant CHO (rCHO) cells frequently used mammalian expression
systems for large-scale production of biopharmaceuticals to satisfy the huge market demand
due to their adaptation capability to suspension culture, high cell growth rate, high protein
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production yield, and resistance to mechanical stress [10–19], mostly when they are used for
stable expression [20, 21].
Overall protein production in bioreactor cultures is a function of total viable cell number
and production yield. However, cell death decreases the protein production; thus, prolongation
of cells’ survival results in enhanced production yield. Therefore, there is a commercial need to
identify methods for prolongation of cells’ lifetime [22, 23]. The cell death in bioreactor
culture occurs due to mainly apoptosis when proteolytic caspases are activated in control of
survival and death genes in consequence of the several conditions such as nutrient shortage
and oxygen deficiency [24, 25], and sometimes autophagy also occurs [26]. The prolongation
of cells’ lifetime brings various benefits such as increasing production yields at diminished
cost via increasing the time of production at one cycle, providing undiminished product
quality, and simplifying downstream processes via preventing exposure of cells to debris
and degradative enzymes [27]. The strategy of the delaying apoptosis via overexpression of
anti-apoptotic genes has been used in several cells such as hybridoma [28, 29], CHO cells [27,
30], and NS0 myeloma cells [31]. The effectiveness of overexpressing anti-apoptotic genes,
such as Bcl-2 or Bcl-xL, on maintaining cell viability is due to several unfavorable bioreactor
production conditions such as limitation of various nutrients, exposure to toxin, shear stress,
oxygen deprivation, and growth factor withdrawal [27, 32, 33]. Overexpressing anti-apoptotic
genes in CHO cells compared to non-expressing cells increased the product titers [27, 34, 35].
Thus, anti-apoptotic cell engineering is a promising strategy to prolong the cell viability and to
increase production yield of recombinant proteins via generating robust cell hosts [36].
Transient gene expression (TGE) is a technique to introduce foreign genetic material to
cells without integration into the chromosome in contrast to the stable transfection; expression
of the genetic material can be traced via a reporter gene usually within 1–2 days post-
transfection [37, 38]. Many copies of a foreign gene are produced in the nucleus and the gene
is transiently expressed to produce proteins in a faster and cheaper way [37–41]. Compared to
stable transfection which requires almost 4–5 months to take the product, TGE requires a
relatively short period, a maximum of 14 days, after transient transfection but low protein yield
is a concern [37, 40]. For this reason, studies have been introduced to improve the foreign
genetic material transfer to different cell lines by effective gene transfection reagents and
electroporation techniques [37–41]. Polyethylenimine (PEI) which forms polyplexes with the
plasmid DNA [40–44] and Lipofectamine® 2000, a cation-lipid formulation that produces
liposomes in aqueous media, are the agents mostly used [38, 41], with a 40–90% transfection
efficiency [40–42]. Serum-free media is used to form uniform polyplexes and liposomes which
make the toxicity of transfection reagents of particular concern in TGE systems [37–44].
Liposomal transfection reagents are reported to be more detrimental to cells than lipid or
polyamine-based reagents [41, 45]. Thus, PEI is selected to be used in transfection for high cell
density culture for large-scale production due to its low toxicity and cost compared to cationic
lipid agents [38–44].
In order to enhance production of anti-TNF-α mAb, anti-apoptotic cell engineering was
evaluated as a BioDesign approach. The aim of the study is to evaluate the effect of
transient expression of anti-apoptotic protein Bcl-xL on the production of anti-TNF-α
mAb. In line with this purpose, anti-TNF-α mAb producing stable CHO cell line was
transiently transfected with the vector expressing anti-apoptotic Bcl-xL gene through both
PEI and LPF. In the first part of the study, optimum transfection parameters were
determined and in the second part, the effect of Bcl-xL overexpression on cell viability
and production efficiency were evaluated.
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Materials and Methods
Plasmid DNA
The construction of Bcl-xL bearing pIRES2EGFP plasmid (Clontech, USA) was described
previously [46]. The glyserol stocks of Escherichia coli DH5-α cells transformed with
pIRES2EGFP/Bcl-xL plasmid were grown in Luria-Bertani (LB) medium (5 g of yeast extract,
2.5 g of tryptone, 2.5 g NaCl) containing 50 μg/mL kanamycine for 14–16 h. pIRES2EGFP/
Bcl-xL plasmid DNAwas purified by using endotoxin-free plasmid maxi kit (Qiagen, 12362,
USA) following users’ instructions.
Cell Culture and Maintenance
Humanized anti-TNF-α mAb, suspension culture, and serum-free medium adapted stable
CHO cell line were obtained from Creative Biolabs, USA. Cells were seeded at a density of
3 × 105 cells/mL in 75-cm2 suspension cell culture flasks and maintained and suspended in
serum-free CD-CHO medium (Gibco, 10743011, USA) supplemented with 0.05% MSX
(methionine sulphoximine) (Millipore, GSS-1015-F, USA) and 1% HT supplement (a liquid
mixture of sodium hypoxanthine (10 mM) and thymidine (1.6 mM)) (Gibco, 11067-030,
USA). Cells were cultured in a humidified incubator with 5% CO2 at 37 °C. Cell line was
routinely tested for mycoplasma contamination on a regular basis.
Transient Transfection
Transfection of CHO Cells with DNA/PEI Complexes
A PEI BMax^ (Mw of 40,000 kDa, linear) (Polysciences, 24765-1, USA) stock solution of
1 mg/mL prepared in ultrapure water, neutralized to pH 7.0 with 1 M HCl, and incubated with
shaking until completely dissolved. The PEI stock solution sterilized by filtration through a
0.22-μm filter, and 1 mL aliquots were stored at −86 °C. CHO cells in exponential phase were
passaged to 1 × 106 cells/mL in maintenance medium on the day prior to transfection. The PEI/
DNA complex was formed in OPTI-MEM I + GlutaMAX I (Gibco, 51985-030, USA) without
serum to support complex formation. DNAwas transferred to tubes at a final concentration of
0.5, 1, or 2 μg/mL in serum-free OPTI-MEMmedium. PEI solution then added 1–8 μL/mL to
the diluted DNA containing tubes drop by drop. The mixture was vortexed for 5 s and then
incubated at room temperature for 30 min. Finally, DNA/PEI mixture transferred to each well
and plates were incubated with gentle shaking at 37 °C in an atmosphere with 5% CO2 and
95% humidity. For the next 7-day period, transfected CHO cells were observed with fluores-
cent microscope and cells were counted by ImageJ program.
Transfection of CHO Cells with DNA/Lipofectamine 2000 Complexes
CHO cells were transfected with lipofectamine-2000 (LPF) (Invitrogen, 11668019, USA) by
using the product protocol. Briefly, CHO cells in exponential phase were passaged to 1 × 106
cells/mL in maintenance medium on the day prior to transfection. The first mixture was
prepared by adding 0.5, 1, or 2 μg/mL DNA to serum-free OPTI-MEM medium containing
tubes. The mixture was vortexed for 5 s and incubated at room temperature for 15 min. In a
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second mixture, Lipofectamine 2000 was transferred to different tubes by diluting 1–8 μL/mL
of serum-free OPTI-MEM I + GlutaMAX I medium. LPF dilution was vortexed and incubated
before getting mixed. After this period, these two tubes were mixed gently with each other and
vortexed for 5 s just before the incubation at room temperature for 30 min. Finally, DNA/
Lipofectamine mixture was transferred to each well and plates were incubated at 37 °C in an
atmosphere with 5% CO2 and 95% humidity for 3 h to allow the transfection. Cultures were
then diluted with an equal volume of growth medium and were incubated with gentle shaking
at 37 °C in an atmosphere with 5% CO2 and 95% humidity. Transfected CHO cells were
evaluated with fluorescent microscope and cells were counted by ImageJ program.
Assessment of Transfection Efficiency by ImageJ
Light and fluorescent microscope images of the cells were automatically counted by ImageJ 1.48
program. Briefly, the microscope photographs were color images (RGB), so they were converted
to gray scale before proceeding: Edit-Options-Conversions steps were set and Bscale when
converting^ option was checked. After the Image-Type-16bit (8bit) option was checked, the
images become gray scale. Image-Adjust-Threshold (Ctrl + Shift + T) steps were set on gray scale
images to highlight all of the structures wewant to count. To highlight, either use the sliders or use
the Bset^ button to type in a known range of pixel intensities (if you want to threshold a whole set
of images the same way, for instance). Different highlight is given to each image when manual
highlighting is performed with the slider. When BDark background^ is selected, the background
will be highlighted with white, and cells will be in black color. Depending on the cell density, the
slider was kept between 6 and 11 in fluorescent pictures and 65–80 in light pictures. After that,
Process-Subtract background steps were set and Brolling ball^ option was checked to determine
and to destroy extra dirtiness after the highlight. Once the area highlighted Bapply^ option was
clicked, this will create a binary version of the imagewith only two pixel intensities: black = 0 and
white = 255. When we had particles that have merged together, Process-Binary-Watershed steps
were set. This option can often (but not always) accurately cut them apart by adding a 1 pixel
thick line where it feels the division should be. At this stage, the imagemust be 8-bit type, and this
can be repeated a few times until black parts are falling apart. Finally, Analyze-Analyze Particles
steps were set, and the images were inch Bpixel units^ optionwas checked and BCircularity: 0.00–
1.00^ option was chosen. BSize^was set between B100-infinity^ and B30-infinity^ depending on
the intensity of fluorescence in fluorescent images and cell morphology in light images. After all
of the steps, Bsummarize^ options were checked and cell numbers were counted.
Staurosporine Treatment and Quantification of Cell Death
Staurosporine (Sigma, S4400, USA) was used to induce apoptosis, which is effectively used in
a wide variety of cell types [47]. Firstly, 1 mM staurosporine stock solution was prepared by
dissolving in DMSO (Millipore, 1.02952.2500, USA). Staurosporine stock solution was added
to the transfected cell culture at a concentration of 1 × 106 cells/mL at final concentration of
1 μM after 48 h of transfection. Cells were incubated with staurosporine for 48 h. Cell
viabilities in the populations were analyzed by trypan blue dye exclusion assay (Applichem,
A0668, Germany) on 3, 5, and 7 days after transfection. Also, after counting on the seventh
day of culture, LIVE/DEAD cell viability assay kit (Molecular Probes, L3224, USA) was used
to visualize cell viability according to manufacturer’s instructions at eighth day of transfection
which stains the live cells green and dead cells red.
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Determination of Anti-TNF-α Quantity by ELISA
Optimization of indirect enzyme-linked immunosorbent assay (ELISA) was done according to
Nalbantsoy et al. to be used for determining the amount of mAbs produced [48]. Humira®
(Abbott Laboratories, Abbott Park, IL), adalimumab, was used as a positive control which is
the commercial biosimilar of the humanized anti-TNF-α antibody produced by the stable CHO
cell line used in this study. First, recombinant TNF-α antigen (Gibco, PHC3011, USA) was
prepared at the appropriate concentration (100 ng/100 μL) in coating buffer (0.05 M
carbonate-bicarbonate buffer (CBB), pH 9.6), then added to each well of 96-well immunoplate
(PolySorp Nunc-Immuno plate, Sigma, M0661, USA) and incubated at +4 °C overnight. The
next day, each well was washed (100 μL/well) 3 × 5 min with T-PBS (1× phosphate buffer
solution containing 0.05% Tween 20) solution. After blocking was made 30 min at room
temperature in 0.5% T-PBS (w/v) with BSA solution (200 μL/well), wells were washed
(100 μL/well) as before. At the end of this time, the appropriate dilutions of the samples were
added (100 μL/well) and incubated 1 h at room temperature, then wells were washed again.
After the conjugate solution (1:10,000 goat anti-human IgG conjugated with HRP—whole
antibody diluted in 1× PBS) (Invitrogen-Novex, 10691234, USA) was added (100 μL/well)
and incubated for 1 h at room temperature, washing process was performed one more time.
Finally, 100 μL substrate solution which consists of OPD (o-Phenylenediamine
dihydrochloride; Sigma, P8412, USA) at a final concentration of 0.4 mg/mL in 75 mL
0.05 M phosphate-citrate buffer and 30 μL of 30% H2O2 was added, and incubated for
30 min at room temperature at dark. After the incubation, stop solution (97–98% 3 M
H2SO4) was added (50 μL/well) and plates were read at 450 nm wavelength by spectropho-
tometer (SpectraMax 190 Molecular Devices, USA). mAb titers were calculated by using the
following Eq. [49]:
Y absorbance@450nmð Þ ¼ 0:06170 xX anti‐TNF α;mg=mLð Þ þ 0:07114
Also, product yield coefficients (Yp/x) were calculated by plotting anti-TNF-α production
(ng) against cell number in the cultures. In this calculation, logarithmic cell growth phase
(between days 3 and 5 of culture) was considered.
Statistical Analysis
All assays were repeated at least three times to ensure reproducibility and three replicates of
each group were performed in each test. Statistical significance of differences between two
groups was evaluated by Student’s unpaired t test and multi-group comparisons were per-
formed using two-way analysis of variance (ANOVA) followed by Tukey’s post hoc test by
Prism 6.0 (GraphPad Software, Inc., San Diego, CA, USA). Data are presented as mean (SD)
and the level of p < 0.05 was considered as statistically significant.
Results
Transfection of CHO Cells with DNA/PEI Complexes
Before evaluation of the potential positive effects of Bcl-xL transfection on anti-TNF-α
production, transfection efficacy of CHO cells by either Bcl-xL bearing or not bearing
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pIRES2EGFP–PEI complexes were optimized. It is known that transfection efficiency of
suspended CHO cells with PEI is greatly affected by the ratio of DNA:PEI and DNA
concentration. In this research, DNA:PEI ratios which were chosen for the experimental sets
include 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, and 1:8 according to the previous studies [41, 50–53].
Fractional values (i.e., 1:1.8, 1:3.9, 1:4.5) were selected by calculating nitrogen-phosphorus
ratios [54]. As for DNA concentration, 0.5, 1, and 2 μg/mL were evaluated in the procedures
of transfection using PEI. According to the results, when CHO cells were transfected with
0.5 μg/mL DNA and DNA:PEI ratios of 1:5, transfected cells expressing EGF were hardly
observed (Fig. 1). Furthermore, increasing the ratio of DNA:PEI did not increase the trans-
fection rate due to the small amount of DNA (Fig. 2). However, when the amount of DNAwas
used as 1 μg/mL and above, a large number of transfected cells were observed for all
DNA:PEI ratios. Transfection efficiencies (percentage of EGFP expressing cells) were quan-
tified through cell counting with ImageJ software. According to these quantitation data,
Fig. 1 Fluorescence and light microscopy images of CHO cells non-transfected (control) and transfected by 0.5,
1, or 2 μg pIRES2EGFP-empty or pIRES2EGFP-Bcl-xL 48 h after treatment with DNA-PEI complexes at the
ratios of 1:5 and 1:6. (scale bar: 100 μm)
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transfection efficiency of cells treated with 1 μg/mL DNAwas significantly higher than cells
treated with 0.5 μg/mL DNA for DNA:PEI ratios of 1:2 (p < 0.01), 1:4 (p < 0.001), 1:6, 1:7,
and 1:8 (p < 0.0001) (Fig. 3a). Transfection efficiencies were increased by 283, 447, and 400%
compared to experimental groups that DNA concentration of 0.5 μg/mL was used when
DNA:PEI ratios of 1:6, 1:7, and 1:8 were used, respectively, with DNA concentration of 1 μg/
mL. Moreover, it was seen that different DNA:PEI ratios did not significantly affect transfec-
tion efficiencies except for DNA:PEI ratio of 1:8 in the experiments of transfection with 0.5 μg
DNA (Fig. 3a). Transfection efficiency of cells transfected with DNA:PEI ratio of 1:8 and with
0.5 μg/mL DNA was higher only than cells treated with ratios of 1:1.8, 1:2, 1:4, and 1:4.5
(p < 0.05) with the transfection efficiency of 1.14%. Due to these results, 1 μg/mL DNA
concentration resulting higher transfection efficiencies compared to 0.5 μg/mL was chosen for
following experiments. The results showed that transfection efficiencies of cell groups treated
by DNA:PEI ratios of 1:6, 1:7, and 1:8 were significantly higher than all other groups when
Fig. 2 Fluorescence and light microscopy images of CHO cells non-transfected (control) and transfected by 0.5,
1, or 2 μg pIRES2EGFP-empty or pIRES2EGFP-Bcl-xL 48 h after treatment with DNA-PEI complexes at the
ratios of 1:7 and 1:8. (scale bar: 100 μm)
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1 μg/mL DNA was used for transfection with the transfection efficiency of 2.44, 3.87, and
5.72%, respectively. Therefore, these three DNA:PEI ratios 1:6, 1:7, and 1:8 and additionally
DNA:PEI ratio of 1:5 were chosen for the following investigations to assess the effect of
transfection with plasmid bearing Bcl-xL on cell viability. Moreover, besides 1 μg/mL DNA
concentration, 2 μg/mL DNAwas used to test whether transfection efficiency was increased or
not with these chosen DNA:PEI ratios. As a result of these evaluations, it was observed that
transfection efficiency of cell group transfected by 2 μg/mL DNAwas significantly higher than
cell group transfected by 1 μg/mL DNA only for the cell group transfected by DNA:PEI ratio
of 1:6 (p < 0.05) with an increase of transfected cell ratio by 57.7%, and the difference of
Fig. 3 Transfection efficiencies of cells transfected a by 0.5 or 1 μg pIRES2EGFP-Bcl-xL 48 h after treatment
with DNA-PEI complexes at the DNA:PEI ratios of 1:1 to 1:8 and b by 1 or 2 μg pIRES2EGFP-Bcl-xL 48 h
after treatment with DNA-PEI complexes at the ratios of 1:5 to 1:8. The change of percentage of cells transfected
by c 1 μg and d 2 μg pIRES2EGFP-Bcl-xL after treatment with DNA-PEI complexes at the ratios of 1:5 to 1:8
from day to day. The change of percentage of cell viabilities transfected by e 1 μg and f 2 μg pIRES2EGFP-Bcl-
xL after treatment with DNA-PEI complexes at the ratios of 1:5 to 1:8 from day to day (control group was non-
transfected cells). All percentages of transfected cells were calculated by evaluation of GFP expressing cells in
the population by observation under fluorescent microscope. Significant differences between experimental
groups are represented in the graph as *p < 0.05, ***p < 0.001, ****p < 0.0001. Data are presented as
mean ± SD. Two-way ANOVA followed by Tukey’s post hoc test
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transfection efficiencies between cells transfected by 1 and 2 μg/mL DNAwas not significant
for other transfection groups (1:7 and 1:8) (Fig. 3b). In spite of the fact that difference of
transfection efficiencies between cell groups transfected with these two DNA concentrations
were not consistent for all tested DNA:PEI ratios, transfection by 2 μg/mL DNAwas chosen as
a more promising concentration in respect to efficiency of transfection for further analyses.
Moreover, transfection efficiency of cell groups transfected by DNA:PEI ratio of 1:5 was
significantly lower than other three transfected groups both for groups transfected with 1
and 2 μg/mL DNA concentrations (Fig. 3b). Therefore, DNA:PEI ratio of 1:5 was
excluded for following examinations consisting of analyses of apoptotic tendency of cells
transfected with Bcl-xL-bearing plasmid after staurosporine treatment and production of
anti-TNF-α by these cells. However, there was no any significant difference between
transfection efficiencies of cell groups transfected by DNA:PEI ratio of 1:6, 1:7, and 1.8
when 2 μg/mL DNA concentration was used to transfect cells. Therefore, despite insig-
nificancy of transfection efficiency difference between cell groups transfected with these
three ratios, 1:6 and 1:8 were used in further analyses as lowest and highest DNA:PEI
ratios to pursue effects of these ratios. The results also indicated that when cells transfected
with 1 μ/mL DNA, expression of the plasmid bearing GFP besides Bcl-xL was continued
during 7 days without any significant and continuous decrease (Fig. 3c). As expected, no
decrease in ratio of EGF expressing cells was observed when the amount of DNA was
increased to 2 μg/mL for transfection of cells as well (Fig. 3d).
According to the results presented in Fig. 3e, viabilities of cells were significantly higher in
cell groups transfected by Bcl-xL-bearing plasmid compared to non-transfected control group
at second, third, and fourth day after transfection for cells transfected by 1 μg/mL DNA
concentrations. In addition, while cell viability in non-transfected group were decreasing day
by day until the third day of culture due to adaptation of fresh culture condition, cell viabilities
in all transfected groups were not significantly decreased day by day (Fig. 3e). As expected, a
similar trend was observed when two times more DNA amount was used to transfect cells
(Fig. 3f). In brief, in light of the above data, DNA:PEI ratios of 1:6 and 1:8 with using 2 μg/mL
DNA concentration were selected for transfections in further examinations with PEI reagent
because of the fact that these transfection procedures provided higher transfection efficiencies
(4.08 and 4.4%) compared to other transfected groups 48 h after transfection and higher cell
viabilities (approximately an increase by 12%, 48 h after transfection) compared to non-
transfected control group between second and fourth days of transfection.
Transfection of CHO Cells with DNA/Lipofectamine 2000 Complexes
As in the evaluation of efficiency in transfection with PEI, before evaluation of the effects of
Bcl-xL transfection on anti-TNF-α production, the proper conditions for transfection of CHO
cells by either Bcl-xL bearing or not bearing pIRES2EGFP–Lipofectamine (LPF) complexes
were examined. For transfection of CHO cells with LPF, different DNA:LPF ratios (1:1, 1:1.8,
1:2, 1:3, 1:3..9, 1:4, 1:4.5, 1:5, 1:6, 1:7, 1:8) were used correspondingly. Fluorescent micros-
copy observation revealed that the use of 0.5 μg/mL DNAwas insufficient to transfect CHO
cells via LPF for DNA:LPF ratio of 1:1.8. When the amount of DNAwas increased to 1 and
2 μg/mL, a large number of transfected cells were observed (Fig. 4). The quantification of the
images showed that transfection efficiency of cells treated with 1 μg DNA was significantly
higher than cells treated with 0.5 μg DNA for DNA:LPF ratios except for transfection at ratios
of 1:3.9, 1:4.5, 1:5, and 1:6 (p < 0.0001) (Fig. 5a). Based on these results, transfection with
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Fig. 4 Fluorescence and light microscopy images of CHO cells non-transfected (control) and transfected by 0.5,
1, or 2 μg pIRES2EGFP-empty or pIRES2EGFP-Bcl-xL 48 h after treatment with DNA-Lipofectamine (LPF)
complexes at the ratio of 1:1.8. (scale bar: 100 μm)
Fig. 5 Transfection efficiencies of cells transfected a by 0.5 or 1 μg pIRES2EGFP-Bcl-xL 48 h after treatment
with DNA-LPF complexes at the DNA:LPF ratios of 1:1 to 1:8 and b by 1 or 2 μg pIRES2EGFP-Bcl-xL 48 h
after treatment with DNA:LPF complex at ratio of 1:1.8. c The change of percentage of cells transfected by 1 and
2 μg pIRES2EGFP-Bcl-xL after treatment with DNA-LPF complexes at the DNA:LPF ratio of 1:1.8 from day to
day. d The change of percentage of cell viabilities transfected by 1 and 2 μg pIRES2EGFP-Bcl-xL after treatment
with DNA-LPF complexes at the DNA:LPF ratio of 1:1.8 from day to day (control group was non-transfected
cells). All percentages of transfected cells were calculated by evaluation of GFP expressing cells in the population
by observation under fluorescent microscope. Significant differences between experimental groups are repre-
sented in the graph as ****p < 0.0001. Data are presented as mean ± SD. a, c, d Two-way ANOVA followed by
Tukey’s post hoc test. b Two-tailed unpaired Student’s t test
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1 μg/mL DNA concentration was used to choose efficient DNA:LPF ratios. According to
Fig. 5a, transfection by using DNA:LPF ratio of 1:1.8 gave the most efficient transfection
result with a significant difference from all other groups (p < 0.0001). To test whether increase
of DNA concentration was influential or not on transfection efficiencies, besides 1 μg/mL
DNA concentration, 2 μg/mL was also used. However, transfection with increased DNA
concentration did not result in positive effect on transfection efficiency (Fig. 5b). According to
the results presented in Fig. 5b transfection with DNA:LPF ratio of 1:1.8 and 1 μg/mL DNA
concentration gave higher transfection efficiency with 15.03% (1.5-fold) compared to 1 μg/mL
DNA concentration. Due to this reason, transfection by 1 μg DNA was chosen for the most
efficient transfection. Also, the results showed that expression of the plasmid bearing also GFP
was continued during 7 days without significant decrease except for decrease between number
of GFP expressed cells at second day of culture and third day of culture (p < 0.0001) (Fig. 5c).
Transfection procedure by using 1:1.8 DNA:LPF ratio and 1 μg/mL DNA concentration did
not cause a significant decrease in cell viability till the sixth day of culture (Fig. 5d). According
to the results shown in Fig. 5d, viability of cells was significantly higher in cell group
transfected with Bcl-xL-bearing plasmid compared to non-transfected control group at second,
third, and fourth day after transfection with 1 μg/mL DNA concentration (with an increase of
9.16, 10.06, and 3.22%, respectively).
Transfection of CHO Cells with DNA/Lipofectamine 2000 Complexes
As in the evaluation of efficiency in transfection with PEI, before evaluation of the effects of
Bcl-xL transfection on anti-TNF-α production, the proper conditions for transfection of CHO
cells by either Bcl-xL bearing or not bearing pIRES2EGFP–Lipofectamine (LPF) complexes
were examined. For transfection of CHO cells with LPF, different DNA:LPF ratios (1:1, 1:1.8,
1:2, 1:3, 1:3..9, 1:4, 1:4.5, 1:5, 1:6, 1:7, 1:8) were used correspondingly. The results showed
that transfection efficiency of cells treated with 1 μg DNAwas significantly higher than cells
treated with 0.5 μg DNA for DNA:LPF ratios except for transfection at ratios of 1:3.9, 1:4.5,
1:5, and 1:6 (p < 0.0001) (Figs. 4 and 5a). Based on these results, transfection with 1 μg/mL
DNA concentration was used to choose efficient DNA:LPF ratios. According to Fig. 5a,
transfection by using DNA:LPF ratio of 1:1.8 gave the most efficient transfection result with a
significant difference from all other groups (p < 0.0001). To test whether increase of DNA
concentration was influential or not on transfection efficiencies, besides 1 μg/mL DNA
concentration, 2 μg/mL was also used. However, transfection with increased DNA concen-
tration did not result in positive effect on transfection efficiency (Figs. 4 and 5b, c). According
to the results presented in Fig. 3b, transfection with DNA:LPF ratio of 1:1.8 and 1 μg/mL
DNA concentration gave higher transfection efficiency with 15.03% (1.5-fold) compared to
1 μg/mL DNA concentration. Due to this reason, transfection by 1 μg DNAwas chosen for the
most efficient transfection. Also, the results showed that expression of the plasmid bearing also
GFP was continued during 7 days without significant decrease except for decrease between
number of GFP expressed cells at second day of culture and third day of culture (p < 0.0001)
(Fig. 5c). Transfection procedure by using 1:1.8 DNA:LPF ratio and 1 μg/mL DNA concen-
tration did not cause a significantly decrease in cell viability till the sixth day of culture
(Fig. 5d). According to the results shown in Fig. 5d, viability of cells was significantly higher
in cell group transfected with Bcl-xL-bearing plasmid compared to non-transfected control
group at second, third, and fourth day after transfection with 1 μg/mL DNA concentration
(with increase of 9.16, 10.06, and 3.22%, respectively).
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Staurosporine Treatment and Quantification of Cell Death
Staurosporine which is a protein kinase inhibitor was reported as an inducer of apoptosis in
several cell types [47, 55]. Considering optimal transfection conditions stated above,
staurosporine treatment experiments were conducted in order to examine the effect of trans-
fection with Bcl-xL on anti-apoptotic feature of the cell populations. For this examination,
CHO cells were transfected by pIRES2EGFP-empty (as control) or pIRES2EGFP-Bcl-xL by
using 2 μg/mL DNA and the DNA:PEI ratios of 1:6 and 1:8 for transfection with PEI and by
using 1 μg/mL DNA and the DNA:LPF ratio of 1:1.8 for transfection with LPF. Transfected
cells were treated by staurosporine 48 h after transfection to induce apoptosis, and viability of
cells was examined by trypan blue dye exclusion assay 3, 5, and 7 days after transfection and
visualized by LIVE/DEAD assay 8 days after transfection (Fig. 6). It was shown that CHO
cells transfected by Bcl-xL-bearing plasmid had significantly higher cell viability than cells
transfected by empty vector 24 h after induction of apoptosis by staurosporine (p < 0.0001)
(Fig. 7a). Likewise viability of CHO cells transfected by Bcl-xL-bearing plasmid via LPF were
higher compared to control cells transfected by empty vector 24 h after staurosporine treatment
(p < 0.0001) (Fig. 7b). According to the results shown in Fig. 7a, viability of CHO cells
transfected with Bcl-xL-bearing plasmid:PEI complex with ratios of 1:6 and 1:8 were en-
hanced compared to viability of cells transfected by empty vector 24 h after induction of
apoptosis by staurosporine with increases of cell viability by 25.45 and 39.89%, respectively.
As for transfection with Bcl-xL-bearing plasmid:LPF complex with ratio of 1:1.8, cell viability
was enhanced by 38.67% 24 h after induction of apoptosis (Fig. 7b).
Determination of Anti-TNF-α Quantity Produced by the CHO Cell ELISA
To determine whether transfection by Bcl-xL-bearing plasmid increase anti-TNF-α production
in CHO cells or not, determined optimal transfection conditions were used. For determination
of anti-TNF-α production, CHO cells were transfected by pIRES2EGFP-empty (as control) or
pIRES2EGFP-Bcl-xL by using 2 μg/mL DNA and the DNA:PEI ratios of 1:6 and 1:8 for
transfection with PEI and by using 1 μg/mL DNA and the DNA:LPF ratio of 1:1.8 for
transfection with LPF and production of anti-TNF-α was determined by ELISA. It was shown
that CHO cells transfected with Bcl-xL-bearing plasmid had produced significantly higher
level of anti-TNF-α compared to cells transfected by empty vector. According to the results, at
seventh day of transfection, CHO cells transfected with Bcl-xL-bearing plasmid by PEI at 1:6
ratio (p < 0.0001) and 1:8 ratio (p < 0.01) and by LPF at 1:1.8 ratio (p < 0.0001) produced
significantly higher level of anti-TNF-α in comparison with CHO cells transfected with empty
plasmid by the same transfection procedures. While the production of anti-TNF-α in CHO
cells was 134 mg/L after transfection with empty plasmid, the production increased up to
215 mg/L after transfection with Bcl-xL-bearing plasmid:PEI reagent at a ratio of 1:6 with a
1.60-fold increase. In addition, when CHO cells transfected with Bcl-xL-bearing plasmid:PEI
reagent ratio of 1:8, production of anti-TNF-αwas enhanced from 123.17 to 147.17 mg/L with
a 1.19-fold increase. As a control of transfection using LPF reagent, the production of anti-
TNF-α was increased from 96 up to 198 mg/L with 2.07-fold increase (Fig. 8a). In addition,
product yield coefficients (Yp/x; ng/cell) for anti-TNF-α production were calculated taking into
account the logarithmic growth phase of the cells. The results indicated that for all transfection
methods, cells transfected with Bcl-xL had statistically higher Yp/x values than cells transfected
with empty vector. These results also suggest that the cells transfected with LPF showed the
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highest Yp/x value with 0.098 ng/cell. No statistically significant change was observed between
cell groups transfected by the empty vector (Fig. 8b).
Discussion
During the recent years TGE has been under investigation for many researchers in order to
produce proteins in mammalian cell hosts in a short period of time and cost-effectively [8, 43,
56]. In spite of that PEIs are efficient and cost-effective transfection reagents, they provide
lower protein expression for each gene copy delivered than that of viral vectors [57, 58].
Delafosse et al. reported that the use of PEImax to transiently transfect CHO cells provided
Fig. 6 Fluorescence microscopy images of CHO cells, non-transfected (control) and transfected by
pIRES2EGFP-empty or pIRES2EGFP-Bcl-xL by LIVE/DEAD® viability/cytotoxicity assay. The transfection
by PEI was carried out by using 2 μg/mL DNA and the DNA:PEI ratios of 1:6 and 1:8; the transfection by LPF
was carried out by using 1 μg/mL DNA and the DNA:PEI ratio of 1:1.8. Transfected cells also were treated by
staurosporine (STAU) 48 h after transfection to induce apoptosis and viability of cells was observed under
fluorescence microscope 8 days after transfection. Live cells fluoresce green and dead cells with compromised
membranes fluoresce red. (scale bar: 100 μm)
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Fig. 8 a ELISA analysis of anti-TNF-α expression in cells transfected by pIRES2EGFP-empty or
pIRES2EGFP-Bcl-xL after treatment with DNA-PEI complexes at the ratio of 1:6 or 1:8 with 2 μg/mL DNA
or DNA-LPF complexes at the ratio of 1:1.8 with 1 μg/mL DNA. b Product yield coefficients (Yp/x; ng/cell) for
anti-TNF-α production by these cells. Significant differences between experimental groups are represented in the
graph as *p < 0.05, **p < 0.01, ****p < 0.0001. Data are presented as mean ± SD. Two-way ANOVA followed
by Tukey’s post hoc test
Fig. 7 a, b The change of percentage of cell viabilities transfected by pIRES2EGFP-Empty or pIRES2EGFP-
Bcl-xL after treatment with DNA-PEI complexes at the ratio of 1:6 or 1:8 with 2 μg/mL DNA or DNA-LPF
complexes at the ratio of 1:1.8 with 1 μg/mL DNA. Transfected cells also were treated by STAU 48 h after
transfection to induce apoptosis and viability of cells were evaluated by trypan blue dye exclusion assay 3, 5, and
7 days after transfection. Data are presented as mean ± SD. Two-way ANOVA followed by Tukey’s post hoc test
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increased mAb productivities compared to linear PEI (155–230%) [56]. Therefore, in this
study, PEImax was used to transiently transfect CHO cells with Bcl-xL-bearing plasmid. It is
known that DNA amount and the DNA:PEI ratio are among most important parameters for an
efficient protein expression in PEI-mediated transfection [59]. Abbott et al. investigated
transfection efficiencies after transfection with DNA concentrations ranging between 0.5
and1.5 μg/mL and DNA:PEI ratios ranging between 1:11 and 1:3 and showed that expression
levels of cells after transfection with PEImax were increased by lowered DNA:PEI ratio up to
1:9 by using Box–Behnken experimental design [60]. In the first part of this study, to
determine optimum transfection conditions, DNA concentrations ranging between 0.5 and
2 μg/mL and DNA:PEI ratios ranging between 1:1 and 1:8 were used to transiently transfect
CHO cells. The results indicated that transfection efficiency of cells transfected with 1 μg/mL
DNA was significantly higher than cells transfected with 0.5 μg/mL DNA when DNA:PEI
ratios of 1:2, 1:4, 1:6, 1:7, and 1:8 were used. Therefore, it is thought that at least 1 μg/mL
DNA concentration is essential for this transfection procedure and use of 2 μg/mL DNA
concentration resulting in increased transfection for only one experimental group (DNA:PEI
ratio of 1:6). Although in this study 2 μg/mL DNAwas used based on this increase (57.7%)
observed in the experimental group that DNA:PEI ratio of 1:6 was used, 1 μg/mL DNA may
be proper for large-scale production as well. Moreover, the results have indicated that lower
DNA:PEI ratios (1:6, 1:7, and 1:8) provided higher transfection efficiency and higher cell
viability after transfection. However, the increase in transfection efficiency was not continued
when DNA:PEI ratio was decreased below 1:6 (1:7 and 1:8). This result has shown that
PEI:DNA ratio can be decreased to 6:1 at most to maintain efficient transfection in this
procedure. Besides PEI, LPF that is a cation-lipid formulation transfection reagent was used
to transiently transfect CHO cells with Bcl-xL-bearing plasmid. However, it is known that LPF
is not a highly preferable transfection reagent by virtue of its high cost and lower scalability for
large-scale production. Furthermore, transfection efficiencies obtained from cells transfected
with DNA:LPF complexes resulted in considerably different transfection efficiencies ranging
between 3.8 and 15% in this study.
Suppression of apoptosis has been considered a remarkable strategy to enhance product
yield via increasing survival of cells. The anti-apoptotic strategies have been accelerated by
gaining knowledge in the matter of apoptotic cascade and important components in this
process [23, 32, 33]. The bcl-2 anti-apoptotic gene is the mostly investigated and used to
overexpress in commercial cell lines and enhance cell viability [31, 32, 61, 62]. Besides bcl-2,
Bcl-xL, which is bcl-2 family member, has been studied as well for the same purpose [28–30,
63]. Various studies were indicated that the overexpression of Bcl-xL gave better results rather
than Bcl-2 to enhance production in CHO cells [32, 33, 63]. In addition, Templeton et al.
reported that the increase in the total biomass yield through anti-apoptotic engineering
enhances the peak viable cell density and thus enhances the integrated viable cell density that
results in higher recombinant protein production [64].
In this study, the effect of overexpression of Bcl-xL on viability and anti-TNF-α production
of the CHO cell line that stably produces humanized anti-TNF-αmAb were investigated using
different transfection procedures. It was observed that transfection with complex of Bcl-xL-
bearing plasmid:PEI reagent provided enhanced cell viabilities compared to non-transfected
control group (increase by approximately 12%) at the second day of transfection when
DNA:PEI ratio of 1:6 and 1:8 were used in transfection. As for transfection with complex of
Bcl-xL-bearing plasmid:LPF reagent, cell viability was increased by 9% when DNA:LPF ratio
of 1:1.8 was used in transfection. Moreover, staurosporine, which is known to induce
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apoptosis in several cell lines including CHO cells [65], was used to evaluate the anti-apoptotic
activity of Bcl-xL in anti-TNF-α mAb producing stable CHO cells. The results indicated that
transfection with Bcl-xL-bearing plasmid enhanced cell viability with increases between
approximately 25 and 40% after staurosporine treatment depending on changed transfection
parameters. Previous studies indicated that Bcl-xL transfection provided increased cell viabil-
ities in CHO cells with wide range of percentages [27, 33, 66] depending on culture and
transfection parameters. The reason of the fact that increases in cell viabilities after Bcl-xL
transfection were low in this study is transfection efficiencies not exceeding 16%. Anti-TNF-α
mAb producing stable CHO cells did not allow higher expression of the plasmid in transfec-
tion procedures discussed in this research. Zustiak et al. showed that although the growth and
viability of all cultures were similar in Bcl-xL-expressing and Bcl-xL-not-expressing cell
groups, the final product titers were increased significantly by transfection with Bcl-xL [35].
Similarly, in this study despite relatively low increase in cell viability arisen with Bcl-xL
transfection, the production of anti-TNF-α was increased up to 2.07-fold with transfection by
LPF reagent, up to 1.6-fold with transfection by PEI reagent, and product yield coefficients of
cells were increased up to 0.98 via with Bcl-xL transfection. All taken together, it is shown that
overexpression of Bcl-xL provides higher production of anti-TNF-α mAb up to 215 mg/mL
compared to 134 mg/mL producing control group and the strategy discussed in this paper have
a potential for large-scale production of biosimilars through TGE.
Conclusion
The methods for delaying cell apoptosis have been largely considered as a highly promising
and advantageous strategy to increase product yield and quality and reduce production costs in
medical biotechnology applications. Previous studies using anti-apoptotic cell engineering via
overexpression of anti-apoptotic genes have succeeded at different recombinant proteins in
various hosts. In this study, it has been shown that it is possible to delay apoptosis in CHO cells
and induce higher TNF-α antibody production by using overexpression of Bcl-xL anti-
apoptotic protein in trough TGE which can be a promising technology to enhance the
production yield both in biosimilar production that is a growing market in biopharmaceutical
production and in innovators which are entering the pipeline to be clinically evaluated.
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